This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Inflammation				
Inflammation	Phosphoinositide 3-kinase (PI3K)	<p>A study in human cell culture identified quinazolinone-based dual PI3K catalytic subunit-δ- and catalytic subunit-γ-selective inhibitors that could help treat inflammation with reduced toxicity. In human cell cocultures, a PI3Kδ/γ dual inhibitor had an anti-inflammatory effect without the toxicity associated with some pan-PI3K inhibitors. Next steps could include testing the dual inhibitors in preclinical cancer models.</p> <p>CAL-263, an oral, small molecule catalytic subunit-δ-selective PI3K inhibitor from Calistoga Pharmaceuticals Inc., is in Phase I testing to treat rheumatoid arthritis (RA) and asthma.</p> <p>SciBX 3(11); doi:10.1038/scibx.2010.348 Published online March 18, 2010</p>	Patent and licensing status unknown	<p>Williams, O. <i>et al. Chem. Biol.</i>; published online Feb. 26, 2010; doi:10.1016/j.chembiol.2010.01.010</p> <p>Contact: Kevan M. Shokat, University of California, San Francisco, Calif. e-mail: shokat@cmp.ucsf.edu</p>